MBX Biosciences (MBX.US) has submitted an IPO application, with plans to raise up to $100 million in funding.

MBX Biosciences, a biotechnology company focused on precision treatment of endocrine and metabolic diseases, submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission last Friday, targeting to raise up to $100 million to support the development and commercialization of its innovative drugs. Led by its co-founders, MBX Biosciences is dedicated to developing engineered peptide drugs designed to enhance efficacy and safety, including extending duration of action, achieving stability of drug concentration, reducing peak-trough concentration ratio, ensuring sustained exposure to target tissues, and reducing dosing frequency. The company's lead development project, MBX 2109, is a parathyroid hormone peptide aimed at providing a potential long-term alternative therapy for patients with chronic hypoparathyroidism. It is worth noting that MBX Biosciences successfully dosed the first patient in a Phase II clinical trial in August 2024. Since its establishment in Carmel, Indiana in 2018, the company has been driving industry development with its innovative spirit and scientific strength. MBX Biosciences plans to list on the Nasdaq Stock Exchange under the ticker symbol "MBX". The company submitted its IPO application in secret on March 22, 2024. J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities are the joint book-running managers for the transaction. Pricing terms have not yet been disclosed.